TargetBeta
TREM2
triggering receptor expressed on myeloid cells 2 · also TREM-2, Trem2a, Trem2b, Trem2c · V-set domain containing
2 programs in company-led studies act on TREM2, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| SAR448851 | Sanofi | phase 2 | 11 running | – | the company's pipeline |
| Anti-TREM2 Monoclonal Antibody EOS006215rule | iTeos Belgium | phase 1 | 10 running | – | NCIt |
Conditions their studies are in
- Alzheimer Disease, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jul 31, 2029SAR448851 · Sanofi · phase 2 · NCT07688213
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.